FibroGen Phase 3 pamrevlumab trial for DMD fails to meet primary endpoint

KYNTRA BIO, INC.

Primary endpoint (NSAA total score change at week 52) not met: mean difference -0.528 points (p=0.5553).
All secondary endpoints including stair climb velocity and 10-meter walk/run test also not met.
Pamrevlumab was generally safe and well tolerated; SAEs 8.3% pamrevlumab vs 2.8% placebo.
Company evaluating total data and will share full results at a future medical forum.
Interim CEO Thane Wettig expressed disappointment and gratitude to trial participants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.